Published in J Card Fail on April 01, 2008
The burden of atrial fibrillation in the Netherlands. Neth Heart J (2011) 0.94
Determinants of plasma NT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction. Clin Res Cardiol (2008) 0.91
Thyroid hormone replacement therapy attenuates atrial remodeling and reduces atrial fibrillation inducibility in a rat myocardial infarction-heart failure model. J Card Fail (2014) 0.88
Reversal of cardiomyopathy in patients with congestive heart failure secondary to tachycardia. J Interv Card Electrophysiol (2012) 0.82
Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure. Heart Vessels (2011) 0.78
Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation. Herz (2014) 0.77
Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clin Res Cardiol (2017) 0.76
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Universal definition of myocardial infarction. Circulation (2007) 11.69
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J (2007) 7.34
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2012) 6.42
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med (2009) 5.34
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J (2006) 3.62
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Moderate procedural sedation and opioid analgesia during transradial coronary interventions to prevent spasm: a prospective randomized study. JACC Cardiovasc Interv (2013) 2.65
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62
Acute heart failure syndromes: current state and framework for future research. Circulation (2005) 2.47
The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J (2009) 2.28
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol (2013) 1.89
Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med (2006) 1.73
2014 ESC/EACTS guidelines on myocardial revascularization. Rev Esp Cardiol (Engl Ed) (2015) 1.69
Effective sleep apnoea treatment improves cardiac function in patients with chronic heart failure. Int J Cardiol (2012) 1.68
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Is there a human homologue to the murine proteolysis-inducing factor? Clin Cancer Res (2007) 1.59
Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur J Heart Fail (2012) 1.56
Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J (2013) 1.55
Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail (2012) 1.53
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail (2013) 1.53
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. G Ital Cardiol (Rome) (2009) 1.52
Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol (2006) 1.45
Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J (2010) 1.42
Temporary assist device for postcardiotomy cardiac failure. Ann Thorac Surg (2004) 1.40
Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol (2009) 1.38
EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail (2013) 1.37
A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J (2008) 1.33
EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail (2010) 1.32
Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol (2005) 1.27
Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol (2011) 1.24
Apoptosis in lung injury and remodeling. J Appl Physiol (1985) (2004) 1.21
Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med (2008) 1.19
Design of the RELAXin in acute heart failure study. Am Heart J (2012) 1.15
Cardiovascular prevention in diabetes mellitus: no magic remedies. J Am Coll Cardiol (2014) 1.08
2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention (2015) 1.08
Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail (2013) 1.06
Association of chronic kidney disease with outcomes in chronic heart failure: a propensity-matched study. Nephrol Dial Transplant (2008) 1.06
Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J (2012) 1.06
Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail (2010) 1.06
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev (2012) 1.05
Clinical and prognostic value of Duke's Activity Status Index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (2008) 1.04
Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail (2009) 1.04
Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail (2011) 1.03
Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J (2005) 1.03
Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs (2008) 1.03
Hyponatremia in heart failure. Heart Fail Rev (2008) 1.01
Depression in coronary artery disease: novel pathophysiologic mechanisms and therapeutic implications. Int J Cardiol (2006) 1.00
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail (2013) 1.00
Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J (2008) 0.99
Successful retrieval of a coronary stent dislodged in the brachial artery by means of improvised snare and guiding catheter. Int J Angiol (2011) 0.98
Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score. Int J Cardiol (2011) 0.97
ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Rev Esp Cardiol (2009) 0.97
Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. Eur J Heart Fail (2013) 0.97
Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail (2012) 0.97
Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Eur J Heart Fail (2011) 0.96
The rationale for an acute heart failure syndromes clinical trials network. J Card Fail (2009) 0.95
Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol (2009) 0.95
Epidemiology of acute heart failure syndromes. Heart Fail Rev (2007) 0.94
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail (2015) 0.93
Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study. Eur J Heart Fail (2009) 0.92
Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure. Eur J Heart Fail (2009) 0.92
Society of Chest Pain Centers Recommendations for the evaluation and management of the observation stay acute heart failure patient: a report from the Society of Chest Pain Centers Acute Heart Failure Committee. Crit Pathw Cardiol (2008) 0.91
Darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 0.91
Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. Eur J Heart Fail (2014) 0.90
Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists. Pharmacol Toxicol (2003) 0.90
[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol (2007) 0.90
Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol (2006) 0.88
Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient-parts 1-6. Acute Card Care (2009) 0.88
Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail (2014) 0.87
Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail (2008) 0.87
Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil (2008) 0.87
Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis (2007) 0.87
Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Card Fail (2009) 0.86
Successful treatment of heart failure with devices requires collaboration. Eur J Heart Fail (2008) 0.86
Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail (2012) 0.85
The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail (2015) 0.85
Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol (2005) 0.85
Diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases. Heart Lung (2008) 0.85
Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost (2012) 0.84
Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity. Clin Res Cardiol (2014) 0.84